SENSUS HEALTHCARE INC (SRTS)
US81728J1097 - Common Stock
Taking everything into account, SRTS scores 6 out of 10 in our fundamental rating. SRTS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. SRTS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SRTS may be a bit undervalued, certainly considering the very reasonable score on growth This makes SRTS very considerable for value investing!
1. Profitability
1.1 Basic Checks
SRTS had positive earnings in the past year.
SRTS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: SRTS reported negative net income in multiple years.
In the past 5 years SRTS always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 15.56%, SRTS belongs to the best of the industry, outperforming 96.26% of the companies in the same industry.
SRTS has a better Return On Equity (17.20%) than 93.05% of its industry peers.
SRTS has a better Return On Invested Capital (17.59%) than 97.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.56% | ||
| ROE | 17.2% | ||
| ROIC | 17.59% |
ROA(3y)18.8%
ROA(5y)5.48%
ROE(3y)22.42%
ROE(5y)5.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of SRTS (22.54%) is better than 94.65% of its industry peers.
SRTS has a better Operating Margin (28.91%) than 96.26% of its industry peers.
SRTS's Gross Margin of 60.90% is fine compared to the rest of the industry. SRTS outperforms 62.03% of its industry peers.
SRTS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.91% | ||
| PM (TTM) | 22.54% | ||
| GM | 60.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.68%
GM growth 5Y-2.08%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so SRTS is creating value.
SRTS has about the same amout of shares outstanding than it did 1 year ago.
SRTS has more shares outstanding than it did 5 years ago.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SRTS has an Altman-Z score of 14.81. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SRTS (14.81) is better than 91.44% of its industry peers.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 14.81 |
ROIC/WACC1.91
WACC9.21%
2.3 Liquidity
A Current Ratio of 10.52 indicates that SRTS has no problem at all paying its short term obligations.
SRTS has a better Current ratio (10.52) than 93.05% of its industry peers.
A Quick Ratio of 7.89 indicates that SRTS has no problem at all paying its short term obligations.
SRTS has a Quick ratio of 7.89. This is amongst the best in the industry. SRTS outperforms 91.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.52 | ||
| Quick Ratio | 7.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1050.00% over the past year.
SRTS shows a strong growth in Revenue. In the last year, the Revenue has grown by 65.63%.
The Revenue has been decreasing by -1.58% on average over the past years.
EPS 1Y (TTM)1050%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.78%
Revenue 1Y (TTM)65.63%
Revenue growth 3Y36.58%
Revenue growth 5Y-1.58%
Sales Q2Q%126.76%
3.2 Future
The Earnings Per Share is expected to grow by 148.41% on average over the next years. This is a very strong growth
SRTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.96% yearly.
EPS Next Y1362%
EPS Next 2Y366.48%
EPS Next 3Y214.32%
EPS Next 5Y148.41%
Revenue Next Year72.41%
Revenue Next 2Y46.72%
Revenue Next 3Y42.26%
Revenue Next 5Y33.96%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SRTS is valuated correctly with a Price/Earnings ratio of 12.46.
Compared to the rest of the industry, the Price/Earnings ratio of SRTS indicates a rather cheap valuation: SRTS is cheaper than 95.72% of the companies listed in the same industry.
SRTS is valuated cheaply when we compare the Price/Earnings ratio to 27.73, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 10.88, which indicates a very decent valuation of SRTS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRTS indicates a rather cheap valuation: SRTS is cheaper than 95.72% of the companies listed in the same industry.
SRTS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.46 | ||
| Fwd PE | 10.88 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SRTS is valued cheaply inside the industry as 97.33% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SRTS is valued a bit cheaper than the industry average as 74.33% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.71 | ||
| EV/EBITDA | 7.72 |
4.3 Compensation for Growth
SRTS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SRTS's earnings are expected to grow with 214.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y366.48%
EPS Next 3Y214.32%
5. Dividend
5.1 Amount
No dividends for SRTS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENSUS HEALTHCARE INC
NASDAQ:SRTS (12/20/2024, 8:00:00 PM)
After market: 7.24 +0.14 (+1.97%)7.1
-0.11 (-1.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners20.68%
Inst Owner Change18.7%
Ins Owners17.77%
Ins Owner Change-0.16%
Market Cap116.37M
Analysts82
Price Target11.73 (65.21%)
Short Float %3.66%
Short Ratio2.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)553.25%
Min EPS beat(2)320.23%
Max EPS beat(2)786.28%
EPS beat(4)4
Avg EPS beat(4)391.25%
Min EPS beat(4)108.94%
Max EPS beat(4)786.28%
EPS beat(8)5
Avg EPS beat(8)128.69%
EPS beat(12)7
Avg EPS beat(12)93.24%
EPS beat(16)11
Avg EPS beat(16)93.11%
Revenue beat(2)2
Avg Revenue beat(2)38.18%
Min Revenue beat(2)29.36%
Max Revenue beat(2)47%
Revenue beat(4)4
Avg Revenue beat(4)60.38%
Min Revenue beat(4)11.39%
Max Revenue beat(4)153.76%
Revenue beat(8)4
Avg Revenue beat(8)17%
Revenue beat(12)7
Avg Revenue beat(12)18.19%
Revenue beat(16)9
Avg Revenue beat(16)19.92%
PT rev (1m)2.22%
PT rev (3m)7.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.58%
EPS NY rev (1m)9.55%
EPS NY rev (3m)16.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.2%
Revenue NY rev (1m)6.38%
Revenue NY rev (3m)6.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.46 | ||
| Fwd PE | 10.88 | ||
| P/S | 2.82 | ||
| P/FCF | 55.71 | ||
| P/OCF | 43.73 | ||
| P/B | 2.15 | ||
| P/tB | 2.15 | ||
| EV/EBITDA | 7.72 |
EPS(TTM)0.57
EY8.03%
EPS(NY)0.65
Fwd EY9.19%
FCF(TTM)0.13
FCFY1.8%
OCF(TTM)0.16
OCFY2.29%
SpS2.52
BVpS3.3
TBVpS3.3
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.56% | ||
| ROE | 17.2% | ||
| ROCE | 21.85% | ||
| ROIC | 17.59% | ||
| ROICexc | 29.95% | ||
| ROICexgc | 29.95% | ||
| OM | 28.91% | ||
| PM (TTM) | 22.54% | ||
| GM | 60.9% | ||
| FCFM | 5.06% |
ROA(3y)18.8%
ROA(5y)5.48%
ROE(3y)22.42%
ROE(5y)5.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.68%
GM growth 5Y-2.08%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 273.68% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 21.9% | ||
| Profit Quality | 22.44% | ||
| Current Ratio | 10.52 | ||
| Quick Ratio | 7.89 | ||
| Altman-Z | 14.81 |
F-Score7
WACC9.21%
ROIC/WACC1.91
Cap/Depr(3y)51.53%
Cap/Depr(5y)55.46%
Cap/Sales(3y)0.59%
Cap/Sales(5y)1.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1050%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.78%
EPS Next Y1362%
EPS Next 2Y366.48%
EPS Next 3Y214.32%
EPS Next 5Y148.41%
Revenue 1Y (TTM)65.63%
Revenue growth 3Y36.58%
Revenue growth 5Y-1.58%
Sales Q2Q%126.76%
Revenue Next Year72.41%
Revenue Next 2Y46.72%
Revenue Next 3Y42.26%
Revenue Next 5Y33.96%
EBIT growth 1Y763.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year353.9%
EBIT Next 3Y102.64%
EBIT Next 5Y101.39%
FCF growth 1Y-68.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.55%
OCF growth 3YN/A
OCF growth 5YN/A